Stereotaxis(US:STXS)2020-11-09 20:31Financial Data and Key Metrics Changes - Revenue for Q3 2020 totaled $8.7 million, a 6% increase from $8.2 million in Q3 2019, primarily due to the installation of the first Genesis system, partially offset by lower recurring revenue from pandemic-related reductions in procedure volumes [24][25] - Gross margin for the quarter was 54% of revenue, with gross margin on recurring revenue at 86% [25] - Operating expenses decreased to $6.2 million from $6.4 million in the prior year, reflecting increased R&D investment offset by reduced sales and marketing activity [26] - Operating loss and net loss for the quarter were $1.6 million, with adjusted negative free cash flow of $0.2 million [27] - Cash and cash equivalents at quarter-end were $43.8 million, with an expectation to end the year with over $43 million [27] Business Line Data and Key Metrics Changes - The Genesis robotic systems were successfully installed at Helsinki University and Banner University, treating approximately 100 patients for various arrhythmias [5][6] - The Model S Imaging System was utilized for several dozen non-robotic procedures in the Genesis labs, demonstrating high reliability with no downtime [7][10] Market Data and Key Metrics Changes - The macro environment has shown gradual improvement, with hospitals beginning to return to normal capital planning despite ongoing budget reductions and delayed purchasing decisions [11][12] - Preliminary guidance for Genesis system revenue in 2021 is projected between $10 million to $20 million, expected to be split between replacements and new installations [13][29] Company Strategy and Development Direction - The company aims to expand its commercial efforts and has initiated several creative commercial initiatives, including enrolling new fellows into the robotic EP fellows program and enhancing telerobotic capabilities [14][15] - The launch of a proprietary ablation catheter is expected to significantly increase disposable revenue, with initial commercialization and pivotal U.S. trial initiation planned for 2021 [18][20] - The company is focused on building a robust ecosystem of technologies around robotics, with ongoing R&D efforts aimed at expanding into adjacent multibillion-dollar markets [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing discussions with hospitals and the gradual return to normalcy in capital planning, despite the challenges posed by the pandemic [11][96] - The company is optimistic about the potential for increased installations and revenue growth, with a focus on maintaining financial discipline while advancing innovation [29][30] Other Important Information - The company has hosted over 250 virtual visits for potential customers, showcasing the Genesis system and addressing customer concerns [15][87] - The company has implemented an ROI calculator for hospitals to demonstrate the financial benefits of using their systems [90] Q&A Session Summary Question: Guidance for 2021 installs and revenue range - Management indicated that the guidance range of $10 million to $20 million is conservative due to rebuilding capital sales capability and uncertainty in individual processes [33][34][36] Question: Importance of Model S Imaging offering - The Model S Imaging system is crucial for providing a complete lab solution, allowing for significant cost savings and better service for hospitals [40][41] Question: Utilization trends of the Genesis system - Current utilization rates are above average, but it is premature to determine if this is due to the Genesis system or specific customer factors [43] Question: Timing of guidance issuance - The decision to issue guidance was based on positive discussions with potential customers and the need to provide clarity to the investment community [45][46] Question: Sales cycle and support for Genesis sales - The sales cycle varies but generally ranges from three to nine months, with a modest sales force focused on clinical adoption and capital sales [66][68] Question: Impact of telerobotic capabilities on demand - Telerobotic capabilities have allowed for continued engagement with customers despite travel restrictions, contributing positively to the sales funnel [56] Question: Evolution of the pipeline and indications - The company is working on multiple indications simultaneously, with a focus on tools that can be used across various clinical applications [60][62] Question: Sales team structure and distribution - The company has a head of commercialization for different regions and approximately 40 individuals in sales globally, with a focus on clinical support and capital sales [93]